WALTHAM, Mass. — Thermo Fisher Scientific Inc. said it will showcase new mass spectrometry systems and related proteomics technologies at the American Society for Mass Spectrometry Conference, highlighting tools designed to help researchers move more quickly from drug discovery to therapy development.
The Waltham-based company said its latest offerings include the Thermo Scientific Orbitrap Tribrid Apex and Thermo Scientific Orbitrap Excedion mass spectrometers. Thermo Fisher said the platforms combine high-performance instrumentation with AI-enabled analytics to help scientists analyze complex biological data, support multiomics research and improve biopharmaceutical development.
“Innovation in molecular analysis technologies is helping our customers advance scientific discovery and generate deeper biological insights at an unprecedented pace,” said Marc N. Casper, chairman and chief executive officer of Thermo Fisher Scientific. “By combining next-generation Orbitrap platforms with AI-driven analytics, we are now helping scientists transform increasingly complex data into actionable insights to further accelerate the path from discovery to precision therapies.”
The company said the Orbitrap Tribrid Apex Mass Spectrometer builds on its Orbitrap Tribrid technology and is designed for use across multiomics, structural biology, biopharma characterization and small-molecule analysis. Thermo Fisher said the system offers five times greater sensitivity, up to 100% sequence coverage in a single experiment and results up to four times faster than previous-generation instruments.
Thermo Fisher said the system could help researchers study challenging samples on a single platform, identify disease mechanisms earlier and uncover therapeutic targets in areas such as cancer and neurodegenerative disease. The company said the platform supports more than 300 areas of research.
“The Orbitrap Tribrid Apex mass spectrometer is the best proteoform sequencer I’ve seen in my 25 years of translational research,” said Neil Kelleher, Ph.D., director of the Proteomics Center of Excellence at Northwestern University. “It opens an exciting frontier for obtaining deep sequence coverage of proteoforms with unparalleled sensitivity, and these capabilities will enable us to understand complex diseases like never before.”
Thermo Fisher said the Orbitrap Excedion Mass Spectrometer is aimed at pharmaceutical scientists working on more complex drug development pipelines, including GLP-1 therapies, oligonucleotides and antibody-drug conjugates. The company said the system is designed to generate more complete data for decisions related to safety, efficacy and dosing.
According to Thermo Fisher, the Orbitrap Excedion can detect three to five times more compounds in complex samples, helping researchers identify low-abundance or previously undetectable molecules earlier in development. The company said the platform is intended to reduce downstream risk, improve regulatory readiness and support faster progress toward commercialization.
Thermo Fisher said it will also showcase its Olink proteomics platform at ASMS. The platform is designed for high-specificity protein analysis at population scale and is intended to complement Orbitrap-based discovery workflows.
The company said the combined approach is being used in initiatives such as PRECISE, a large biobank program in Asia focused on identifying biomarkers tied to aging and metabolic disease. Thermo Fisher also said recent acquisitions of MSAID and Proteinaceous have added AI, machine learning and proteoform analysis capabilities to its proteomics business.
